决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma.
ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma.
靶向 ALPL-1 的 CAR-T 细胞在临床前模型中显示出治疗 OS 的有效性和特异性,为临床转化铺平了道路。
骨肉瘤(OS)在儿童和年轻成人中仍是一种预后极差的恶性肿瘤,转移性和复发性疾病的结局不佳。由于肿瘤内异质性以及潜在可靶向蛋白存在相当程度的脱靶表达,OS 中的免疫治疗不如在其他一些癌症类型中那样有前景。在此,我们表明嵌合抗原受体(CAR)T 细胞能够成功靶向碱性磷酸酶的一种亚型 ALPL-1,该亚型在原发性和转移性 OS 中高表达且特异性表达。第二代 CAR 构建体的靶标识别元件基于两种抗体,此前已证明这两种抗体可与 OS 发生反应。转导这些 CAR 构建体的 T 细胞在体外环境中以及在最先进的原发性和转移性 OS 原位体内模型中,对 ALPL 阳性细胞介导了高效且有效的细胞毒性,且未对造血干细胞或健康组织产生意外毒性。总之,靶向 ALPL-1 的 CAR-T 细胞在临床前模型中显示出治疗 OS 的有效性和特异性,为临床转化铺平了道路。
Osteosarcoma (OS) remains a dismal malignancy in children and young adults, with poor outcome for metastatic and recurrent disease. Immunotherapies in OS are not as promising as in some other cancer types due to intra-tumor heterogeneity and considerable off-target expression of the potentially targetable proteins. Here we show that chimeric antigen receptor (CAR) T cells could successfully target an isoform of alkaline phosphatase, ALPL-1, which is highly and specifically expressed in primary and metastatic OS. The target recognition element of the second-generation CAR construct is based on two antibodies, previously shown to react against OS. T cells transduced with these CAR constructs mediate efficient and effective cytotoxicity against ALPL-positive cells in in vitro settings and in state-of-the-art in vivo orthotopic models of primary and metastatic OS, without unexpected toxicities against hematopoietic stem cells or healthy tissues. In summary, CAR-T cells targeting ALPL-1 show efficiency and specificity in treating OS in preclinical models, paving the path for clinical translation.
MEMBER ACCOUNT
登录成功会直接打开下一页。